Repligen reports record Q3 revenue, completes BioLife acquisition and raises FY‑2026 guidance

Repligen Corp. posted third‑quarter 2026 revenue of $209.3 million, up about 11% year‑over‑year, and adjusted earnings of $0.53 per share. The company closed its BioLife Solutions acquisition in early October, which it said is progressing well and will be slightly dilutive to Q4 earnings but accretive by $0.05 per share in 2027. On the back of the strong quarter, Repligen lifted its full‑year 2026 revenue outlook to a range of $844 million‑$852 million.

The raised revenue guidance expands the market‑size expectations for the year, potentially supporting a higher valuation for the stock (the company notes the guidance increase reflects the BioLife contribution). The acquisition’s expected $0.05 EPS accretion in 2027 signals incremental earnings upside for shareholders.

  • 1Q3 2026 reported revenue was $209.3 million, an increase of 11% year‑over‑year (reported) and 12.5% organic.
  • 2Adjusted earnings per share for the quarter were $0.53 on a fully diluted basis.
  • 3The company completed the BioLife Solutions acquisition in October 2026.
  • 4Full‑year 2026 revenue guidance was raised to $844 million‑$852 million.
  • 5A $41.2 million intangible‑asset impairment charge contributed to a GAAP loss of $0.68 per share.
  • 6Management said the BioLife acquisition will be slightly dilutive to Q4 earnings but expected to add $0.05 per share to EPS in 2027.
  • Material 8 reports full‑year revenue guidance of $848 million, which differs from the $844‑$852 million range in other sources.

Sources